> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period Determined for Dojolvi
- URL: https://www.fdaweb.com/regulatory-review-period-determined-for-dojolvi/
- Published: 2021-11-09T12:00:00.000Z
- Updated: 2026-09-14T17:21:54.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5150540

*Federal Register* news: FDA has determined for patent extension purposes the regulatory review period for Ultragenyx’s Dojolvi (triheptanoin), indicated as a source of calories and fatty acids for treating pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders. The review period is 2,511 days, which includes 2,175 days that occurred during the testing phase and 336 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-11-09/pdf/2021-24435.pdf?ref=fdaweb.com).